Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713122 | 1.00 | CHRM5 (0.43) | CHRM5ADRA2C | |
| SCHEMBL2439970 | 0.98 | CHRM5 (0.46) | CHRM5ADRA2C | |
| SCHEMBL1489984 | 0.93 | CHRM5 (0.46) | CHRM5ADRA2C | |
| SCHEMBL2439043 | 0.91 | CHRM5 (0.50) | CHRM5ADRA2C | |
| SCHEMBL3553234 | 0.86 | CHRM5 (0.46) | CHRM5ADRA2C | |
| SCHEMBL7114598 | 0.85 | ACHE (0.31) | CHRM5ADRA2C | |
| SCHEMBL3558127 | 0.84 | ADRA2C (0.50) | CHRM5ADRA2C | |
| SCHEMBL7470700 | 0.84 | ACHE (0.31) | — | |
| SCHEMBL665254 | 0.84 | GAA (0.36) | — | |
| SCHEMBL666969 | 0.84 | GAA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | claimed |
| EP-2888252-B1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORP (US) | 2017-06-07 | — | — | EP | claimed |
| EP-3122743-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Azevan Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | claimed |
| US-20160264535-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2016-09-15 | — | — | US | claimed |
| EP-2576536-B1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | UNIV QUEENSLAND (AU) | 2016-09-14 | — | — | EP | claimed |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2016-07-07 | — | — | US | claimed |
| EP-3030550-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | Vichem Chemie Kutató KFT (HU) | 2016-06-15 | — | — | EP | claimed |
| US-9328078-B2 | Benzofurazan anti-amyloid compounds and methods | TREVENTIS CORPORATION (US) | 2016-05-03 | — | — | US | claimed |
| WO-2015148962-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS, INC. (US) | 2015-10-01 | — | — | WO | claimed |
| US-20150266838-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION | 2015-09-24 | — | — | US | claimed |
| US-6521611-B2 | 2-(azetidin-2-on-1-yl) acetic acid derivatives; treatment of obsessive-compulsive disorder | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| EP-0939632-A4 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | LILLY CO ELI (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | BRUNS ROBERT F (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| US-6204260-B1 | 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES | ELI LILLY AND COMPANY | 2001-03-20 | — | — | US | claimed |
| EP-0939632-A1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1997030707-A1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-28 | — | — | WO | claimed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | claimed |
| WO-1994010142-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | CHRM5 1971/4885ADRA2C 104/4885 |
| US-20150266838-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | PRNP, TTR, PSEN1 | CHRM5 531/4885ADRA2C 222/4885 |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | FLT3, BCR, STK3 | CHRM5 4282/4885ADRA2C 3210/4885 |
| US-20160264535-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | PRNP, TTR, PSEN1 | CHRM5 531/4885ADRA2C 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.